Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDP-123 (Arazlo) Phase 3 in Acne Vulgaris
NCT03168321Phase 3Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Jun 2017
- Primary completion
- Jun 2018
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in acne vulgaris comparing IDP-123 Lotion with IDP-123 Vehicle Lotion (2 arms). Primary endpoints: Absolute Change in Mean Lesion Counts at 12 weeks and Percentage of Subjects with Treatment Success on EGSS at 12 weeks. Started Jun 2017; status: completed.
02
Drugs
tazarotene
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT03168321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03168321.